Dapagliflozin

Generic Name: Dapagliflozin

Brand Names: Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅ClO_₆

CAS Number: 461432-26-8

Unique Ingredient Identifier: 1ULL0QJ8UC

Background: Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...

Indication: Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure

Associated Therapies: -

Clinical Trials

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Phase 4

Completed

Conditions: Hypotension
Heart Failure

Interventions: Drug: Dapagliflozin
Drug: Sacubitril-Valsartan
Drug: Beta blocker
Drug: Mineralocorticoid Receptor Antagonist
Device: Cardiac resynchronization therapy and/or implantable cardioverter defibrillator

First Posted Date: 2020-10-05

Last Posted Date: 2021-08-02

Lead Sponsor: Cheng-Hsin General Hospital

Target Recruit Count: 78

Registration Number: NCT04575675

Locations: 🇨🇳
Cheng Hsin General Hospital, Taipei, Taiwan

Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

Phase 4

Conditions: Heart Failure, Systolic

Interventions: Drug: Dapagliflozin
Device: CardioMEMS

First Posted Date: 2020-09-30

Last Posted Date: 2020-09-30

Lead Sponsor: Scripps Health

Target Recruit Count: 100

Registration Number: NCT04570865

Locations: 🇺🇸
Scripps Clinic, La Jolla, California, United States

Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

Phase 3

Completed

Conditions: Heart Failure
Acute Myocardial Infarction

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2020-09-25

Last Posted Date: 2023-08-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 4017

Registration Number: NCT04564742

Locations: 🇬🇧
Research Site, Worthing, United Kingdom

Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition

Phase 1

Completed

Conditions: Pancreas Cancer
Pancreatic Cancer
Cancer of the Pancreas

Interventions: Drug: Dapagliflozin
Device: BIOSENSE meters

First Posted Date: 2020-09-09

Last Posted Date: 2023-02-14

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 15

Registration Number: NCT04542291

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Phase 4

Completed

Conditions: Proteinuria

Interventions: Drug: Dapagliflozin

First Posted Date: 2020-09-01

Last Posted Date: 2022-06-21

Lead Sponsor: Children's Hospital of Fudan University

Target Recruit Count: 23

Registration Number: NCT04534270

Locations: 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China

Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction

Phase 2

Conditions: Heart Failure, Diastolic

Interventions: Drug: Dapagliflozin
Drug: Placebo

First Posted Date: 2020-07-17

Last Posted Date: 2020-09-22

Lead Sponsor: Mariëlle Scheffer

Target Recruit Count: 26

Registration Number: NCT04475042

Locations: 🇳🇱
OLVG, Amsterdam, Noord-Holland, Netherlands

Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

Phase 2

Active, not recruiting

Conditions: Type2 Diabetes

Interventions: Drug: Semaglutide
Drug: Dapagliflozin

First Posted Date: 2020-06-30

Last Posted Date: 2022-10-21

Lead Sponsor: Region Skane

Target Recruit Count: 200

Registration Number: NCT04451837

Locations: 🇸🇪
Anders Rosengrentest, Malmö, Skane, Sweden

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Standard of care
Drug: EDP1815
Drug: Dapagliflozin
Drug: Ambrisentan

First Posted Date: 2020-05-19

Last Posted Date: 2023-07-28

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 454

Registration Number: NCT04393246

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: insulin
Drug: Dapagliflozin

First Posted Date: 2020-05-13

Last Posted Date: 2022-02-16

Lead Sponsor: Assiut University

Target Recruit Count: 100

Registration Number: NCT04385589

Locations: 🇪🇬
Assiut University, Assuan, Egypt

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

Phase 4

Recruiting

Conditions: Acute Heart Failure
Heart Failure

Interventions: Drug: Placebo
Drug: Dapagliflozin

First Posted Date: 2020-04-27

Last Posted Date: 2023-03-31

Lead Sponsor: The TIMI Study Group

Target Recruit Count: 2400

Registration Number: NCT04363697

Locations: 🇺🇸
TIMI Study Group, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy